Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis

被引:12
|
作者
Alosaimi, Fahad D. [1 ]
AlMulhem, Alaa [2 ]
AlShalan, Hanan [2 ]
Alqazlan, Mohammad [3 ]
Aldaif, Abdulgader [4 ]
Kowgier, Matthew [5 ]
Balasundaram, Janooshsheya [6 ]
Sockalingam, Sanjeev [6 ,7 ]
机构
[1] King Saud Univ, Dept Psychiat, Riyadh, Saudi Arabia
[2] King Saud Univ, Coll Med, Riyadh, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Dept Med Hlth, Riyadh, Saudi Arabia
[4] King Saud Univ, Dept Neurol, Riyadh, Saudi Arabia
[5] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada
[6] Univ Hlth Network, Ctr Mental Hlth, Toronto, ON, Canada
[7] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
来源
关键词
multiple sclerosis; adherence; depression; attachment style; culture; MORTALITY; SEVERITY; DEPRESSION; PREVALENCE; VALIDITY; CARE; TOOL;
D O I
10.2147/PPA.S129678
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Our aim was to identify the impact of psychosocial predictors, specifically relationship style, depressive symptoms, anxiety symptoms, cognitive impairment, and culturespecific disease beliefs, on treatment adherence for multiple sclerosis (MS) patients. Methods: In this cross-sectional observational study, patients from two MS clinics in Saudi Arabia completed self-reported questionnaires focused on MS treatment adherence, physical symptom burden, relationship style, cultural beliefs, depressive symptoms, anxiety, and cognitive impairment. Results: A total of 163 MS patients participated, 81.6% of them were female, and the mean age of the patients was 31.6 years. Mean patient-reported adherence to their MS treatment regimen was 79.47%+/- 25.26%. Multivariate linear regression analysis only identified patients' belief that their MS was due to "supernatural" forces as being significantly negatively associated with MS medication adherence. Conclusion: This study demonstrates the importance of cultural interpretations to MS medication adherence in comparison to psychosocial factors. Education and family involvement in the treatment planning may address this issue and warrant further research.
引用
收藏
页码:513 / 518
页数:6
相关论文
共 50 条
  • [41] Comparing the efficacy of disease-modifying therapies in multiple sclerosis
    Mitsikostas, Dimos D.
    Goodin, Douglas S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 109 - 116
  • [42] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
    Kretzschmar, Benedikt
    Pellkofer, Hannah
    Weber, Martin S.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (04)
  • [43] Assessing the risk of multiple sclerosis disease-modifying therapies
    Ayrignac, Xavier
    Bilodeau, Philippe-Antoine
    Prat, Alexandre
    Girard, Marc
    Labauge, Pierre
    Le Lorier, Jacques
    Larochelle, Catherine
    Duquette, Pierre
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (07) : 695 - 706
  • [44] Impact of Disease-Modifying Therapies on Fatigue in Multiple Sclerosis
    Voelter, H. U.
    Hildebrandt, H.
    Kastrup, A.
    AKTUELLE NEUROLOGIE, 2016, 43 (08) : 511 - 518
  • [45] The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis
    Benedikt Kretzschmar
    Hannah Pellkofer
    Martin S. Weber
    Current Neurology and Neuroscience Reports, 2016, 16
  • [46] Current and future disease-modifying therapies in multiple sclerosis
    Lim, S. Y.
    Constantinescu, C. S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (05) : 637 - 650
  • [47] Disease-modifying therapies and infectious risks in multiple sclerosis
    Winkelmann, Alexander
    Loebermann, Micha
    Reisinger, Emil C.
    Hartung, Hans-Peter
    Zettl, Uwe K.
    NATURE REVIEWS NEUROLOGY, 2016, 12 (04) : 217 - 233
  • [48] Emerging disease-modifying oral therapies for multiple sclerosis
    Losy, Jacek
    Kalinowska-Lyszczarz, Alicja
    JOURNAL OF NEUROIMMUNOLOGY, 2011, 231 (1-2) : 15 - 22
  • [49] Adherence of Adolescents to Multiple Sclerosis Disease-Modifying Therapy
    Thannhauser, Jennifer E.
    Mah, Jean K.
    Metz, Luanne M.
    PEDIATRIC NEUROLOGY, 2009, 41 (02) : 119 - 123
  • [50] Disease-modifying therapies and infectious risks in multiple sclerosis
    Alexander Winkelmann
    Micha Loebermann
    Emil C. Reisinger
    Hans-Peter Hartung
    Uwe K. Zettl
    Nature Reviews Neurology, 2016, 12 : 217 - 233